MX2021013751A - Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos. - Google Patents
Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos.Info
- Publication number
- MX2021013751A MX2021013751A MX2021013751A MX2021013751A MX2021013751A MX 2021013751 A MX2021013751 A MX 2021013751A MX 2021013751 A MX2021013751 A MX 2021013751A MX 2021013751 A MX2021013751 A MX 2021013751A MX 2021013751 A MX2021013751 A MX 2021013751A
- Authority
- MX
- Mexico
- Prior art keywords
- cbl
- inhibitor
- methods
- casits
- protooncogen
- Prior art date
Links
- -1 CYCLOBUTYL CYANO COMPOUNDS Chemical class 0.000 title 1
- 206010025323 Lymphomas Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 229940122650 Cbl-b inhibitor Drugs 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 229940022399 cancer vaccine Drugs 0.000 abstract 2
- 238000009566 cancer vaccine Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000000987 immune system Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 244000309459 oncolytic virus Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849722P | 2019-05-17 | 2019-05-17 | |
| US201962880437P | 2019-07-30 | 2019-07-30 | |
| US201962888870P | 2019-08-19 | 2019-08-19 | |
| US201962888845P | 2019-08-19 | 2019-08-19 | |
| PCT/US2020/033274 WO2020236654A1 (en) | 2019-05-17 | 2020-05-15 | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013751A true MX2021013751A (es) | 2022-01-26 |
Family
ID=70978642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013751A MX2021013751A (es) | 2019-05-17 | 2020-05-15 | Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11530229B2 (enExample) |
| EP (1) | EP3969447A1 (enExample) |
| JP (1) | JP7587528B2 (enExample) |
| CN (1) | CN114206855B (enExample) |
| AU (1) | AU2020278592B2 (enExample) |
| CA (1) | CA3140873A1 (enExample) |
| MX (1) | MX2021013751A (enExample) |
| WO (1) | WO2020236654A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| CA3136348A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| AU2020278592B2 (en) | 2019-05-17 | 2024-10-10 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof |
| MX2021015675A (es) * | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034140A1 (en) * | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for use in adoptive cell therapy |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| JP2024506844A (ja) * | 2021-02-03 | 2024-02-15 | ジェネンテック， インコーポレイテッド | Ｃｂｌ－ｂ阻害剤としてのアミド |
| AR124800A1 (es) * | 2021-02-03 | 2023-05-03 | Genentech Inc | Lactamas como inhibidores cbl-b |
| WO2022217123A2 (en) | 2021-04-08 | 2022-10-13 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds |
| CA3236073A1 (en) | 2021-10-26 | 2023-05-04 | Robert J. Brown | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| AU2022379959A1 (en) | 2021-11-05 | 2024-05-09 | Genentech, Inc. | Lactams as cbl-b inhibitors selective over c-cbl |
| TW202342013A (zh) * | 2022-02-10 | 2023-11-01 | 英屬開曼群島商百濟神州有限公司 | 雜環化合物、其組成物及用其進行治療之方法 |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| US20230414598A1 (en) * | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| EP4554570A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent |
| EP4558504A1 (en) * | 2022-07-18 | 2025-05-28 | Insilico Medicine IP Limited | Cbl-b inhibitors and methods of uses thereof |
| EP4558501A1 (en) * | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| KR20250050018A (ko) | 2022-08-16 | 2025-04-14 | 그렌마크 파머수티칼스 엘티디. | Cbl-b 저해제로서의 치환된 피리디논 화합물 |
| WO2024062363A1 (en) * | 2022-09-21 | 2024-03-28 | Glenmark Pharmaceuticals Ltd | Bicyclic heterocyclic compounds as cbl-b inhibitors |
| WO2024105563A1 (en) * | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
| WO2024112692A1 (en) * | 2022-11-21 | 2024-05-30 | Arvinas Operations, Inc. | Casitas b-lineage lymphoma protooncogene b (cbl-b) degrading compounds and associated methods of use |
| CN115887450B (zh) * | 2022-12-09 | 2024-06-25 | 杭州师范大学 | 角鲨烯化替莫唑胺的合成及其自组装纳米粒的制备和应用 |
| WO2024131939A1 (en) * | 2022-12-23 | 2024-06-27 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
| TW202435863A (zh) | 2023-01-28 | 2024-09-16 | 芬蘭商奧利安公司 | Cbl-b抑制劑 |
| CN121816192A (zh) | 2023-09-14 | 2026-04-07 | 因斯布鲁克医科大学 | 通过抑制NR2f6增强CAR-T细胞疗效 |
| CN118324623A (zh) * | 2024-04-12 | 2024-07-12 | 丽珠集团福州福兴医药有限公司 | 一种2-甲基-4-乙酰基苯甲酸的合成方法 |
| WO2026022742A1 (en) * | 2024-07-23 | 2026-01-29 | Bridgene Biosciences Limited | Cbl-b inhibitor and uses thereof |
| WO2026022749A2 (en) | 2024-07-26 | 2026-01-29 | Aurigene Oncology Limited | Cbl-b inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5273986A (en) | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
| US20070054355A1 (en) | 2003-03-05 | 2007-03-08 | Yuval Reiss | Cbl-b polypeptides, complexes and related methods |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| WO2007072225A2 (en) | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| WO2008033403A2 (en) | 2006-09-13 | 2008-03-20 | The Trustees Of Columbia University In The City Of New York | Agents and methods to elicit anti-tumor immune response |
| AT506041A1 (de) * | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| PL2242749T3 (pl) | 2008-02-05 | 2013-09-30 | Hoffmann La Roche | Nowe pirydynony i pirydazynony |
| CN102762551A (zh) | 2009-12-21 | 2012-10-31 | 拜尔农作物科学股份公司 | 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途 |
| EP2566869B1 (en) | 2010-05-07 | 2016-03-02 | Gilead Connecticut, Inc. | Pyridone and aza-pyridone compounds and methods of use |
| ES2666746T3 (es) | 2010-07-13 | 2018-05-07 | Anthrogenesis Corporation | Métodos para generar linfocitos citolíticos naturales |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| AR086992A1 (es) | 2011-06-20 | 2014-02-05 | Bayer Ip Gmbh | Tienilpiri(mi)dinilpirazoles |
| MX2014005282A (es) | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos de 8-fluoroftalazin-1 (2h) -ona. |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2014040965A1 (en) | 2012-09-13 | 2014-03-20 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| US9382246B2 (en) | 2013-12-05 | 2016-07-05 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| CA2946312A1 (en) | 2014-04-23 | 2015-10-29 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
| MX2017015574A (es) | 2015-06-02 | 2018-08-09 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton. |
| AU2016297362B2 (en) * | 2015-07-17 | 2020-04-16 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as HDAC inhibitors |
| EP3138905A1 (en) | 2015-09-04 | 2017-03-08 | Miltenyi Biotec GmbH | Method for natural killer cell expansion |
| EP4212547A1 (en) | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| EP3254701A1 (en) * | 2016-06-09 | 2017-12-13 | IMBA-Institut für Molekulare Biotechnologie GmbH | Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections |
| CA3042297A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| WO2019063748A1 (en) * | 2017-09-30 | 2019-04-04 | Glaxosmithkline Intellectual Property Development Limited | INHIBITORS OF ROR-GAMMA |
| EP3743063A4 (en) * | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| CA3136348A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| AU2020278592B2 (en) | 2019-05-17 | 2024-10-10 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| AU2020320195A1 (en) | 2019-07-30 | 2022-03-10 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition |
| EP4034140A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for use in adoptive cell therapy |
| US20230024442A1 (en) | 2019-11-08 | 2023-01-26 | Nurix Therapeutics, Inc. | Bifunctional compounds for grading btk via ubiquitin proteosome pathway |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| WO2022217123A2 (en) | 2021-04-08 | 2022-10-13 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds |
| US12018032B2 (en) | 2021-08-20 | 2024-06-25 | Biomea Fusion, Inc. | Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction |
-
2020
- 2020-05-15 AU AU2020278592A patent/AU2020278592B2/en active Active
- 2020-05-15 US US16/875,917 patent/US11530229B2/en active Active
- 2020-05-15 CA CA3140873A patent/CA3140873A1/en active Pending
- 2020-05-15 MX MX2021013751A patent/MX2021013751A/es unknown
- 2020-05-15 EP EP20730876.8A patent/EP3969447A1/en active Pending
- 2020-05-15 WO PCT/US2020/033274 patent/WO2020236654A1/en not_active Ceased
- 2020-05-15 CN CN202080051333.0A patent/CN114206855B/zh active Active
- 2020-05-15 JP JP2021568427A patent/JP7587528B2/ja active Active
-
2022
- 2022-12-19 US US18/068,195 patent/US12049471B2/en active Active
-
2024
- 2024-06-18 US US18/747,129 patent/US20240409555A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230212186A1 (en) | 2023-07-06 |
| JP2022532247A (ja) | 2022-07-13 |
| US11530229B2 (en) | 2022-12-20 |
| EP3969447A1 (en) | 2022-03-23 |
| CN114206855A (zh) | 2022-03-18 |
| US20240409555A1 (en) | 2024-12-12 |
| CN114206855B (zh) | 2024-11-26 |
| US12049471B2 (en) | 2024-07-30 |
| WO2020236654A1 (en) | 2020-11-26 |
| AU2020278592B2 (en) | 2024-10-10 |
| JP7587528B2 (ja) | 2024-11-20 |
| US20210053986A1 (en) | 2021-02-25 |
| AU2020278592A1 (en) | 2021-12-02 |
| CA3140873A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013751A (es) | Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos. | |
| MX2025000627A (es) | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos | |
| MX2024010999A (es) | Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico. | |
| MX2022001199A (es) | Compuestos de urea, amida y heteroarilo sustituido para la inhibicion de cbl-b. | |
| ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| MX2024006824A (es) | Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos. | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| UY38999A (es) | Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos | |
| MX2018009126A (es) | Vectores virales oncoliticos y usos de estos. | |
| AU2012242871A8 (en) | Fused imidazole derivatives useful as IDO inhibitors | |
| BR112019018093A2 (pt) | Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto | |
| MX2021005398A (es) | Terapia del cancer con celulas inmunitarias anti-cd33. | |
| EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
| MX391720B (es) | Terapia combinada para tratar cáncer. | |
| BRPI0416981A (pt) | compostos para tratamento de doenças proliferativas de célula | |
| MX2018002344A (es) | Metodo para tratar el cancer. | |
| NI201100056A (es) | Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyética y su uso para tratar enfermedades mediadas por prostaglandina d2. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| BR112022001912A2 (pt) | Composições celulares compreendendo vetores virais e métodos de tratamento | |
| MX2021015448A (es) | Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas. | |
| NZ737542A (en) | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) | |
| CL2020001358A1 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
| MX2017011298A (es) | Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53. | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| BR112016000874A2 (pt) | vírus de rna oncolítico geneticamente estável, método de fabricação e uso dos mesmos |